search
Back to results

Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis

Primary Purpose

Seborrheic Dermatitis

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SEBORRHEAMEDIS Face Cream
Sponsored by
Kamedis Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Seborrheic Dermatitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject with mild (ISGA=2) to moderate (ISGA=3) facial Seborrheic dermatitis.
  • Male or female aged 18 years or older.
  • Subject who agrees not to use any Seborrheic Dermatitis medication during the study, except for the tested product.
  • Subject is willing to sign an Informed Consent

Exclusion Criteria:

  • Subject pregnant or lactating.
  • Subject has a condition that requires continuous systemic or topical corticosteroid or antimycotic therapy
  • Subject has a severe disease that is likely to interfere with the study conducting
  • Subject has a known sensitivity to any of the ingredients contained in the tested product.
  • Subject is expected to be extensively exposed to the sun during the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Interventional, open label, Safety/Efficacy Study

    Arm Description

    SEBORRHEAMEDIS Face Cream Interventional 30

    Outcomes

    Primary Outcome Measures

    Improvement of overall ISGA. Descriptive Name of scale. Physician dermatology evaluation.

    Secondary Outcome Measures

    Improvement of erythema, desquamation on the target area. Physiological parameter. Physician dermatology evaluation.
    Improvement of pruritus. Physiological parameter. Assessed by subject.
    Number and severity of Adverse Events

    Full Information

    First Posted
    January 6, 2016
    Last Updated
    January 13, 2016
    Sponsor
    Kamedis Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02656368
    Brief Title
    Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
    Official Title
    Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2015 (undefined)
    Primary Completion Date
    December 2015 (Actual)
    Study Completion Date
    December 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Kamedis Ltd.

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
    Detailed Description
    30 subjects will be enrolled to the study. After eligibility is confirmed, subjects will be asked to sign an Informed Consent form. At the baseline visit, the investigator will select a target area on the face. The target area will be evaluated for erythema (redness) and desquamation (scaling) using a 5-point scale: 0 = none, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe. Photography of the target area will be taken. For reference, a fixed object (such as a ruler) will be photographed in the same frame. In addition, the investigator will assess the overall facial lesions using an ISGA based on a 5-point scale. The subject will evaluate his/her pruritis over the past 24 hours, using a 5-point scale: 0 = no itching, 1 = minimal and rare itching, 2= mild itching, (subject is aware of the itching only when relaxed), 3= moderate itching (subject is often aware of the itching, which occasionally disturbs sleep), 4 = severe and constant itching. Subjects will be instructed to use SEBORRHEAMEDIS Face Cream twice a day, morning and evening, for a consecutive period of 42 days. In addition to the baseline visit (day 0), subjects will be asked to come to the clinic for two follow-up visits at days 14 and 28 and for a final visit at day 42. A flexibility of ±2 days will be allowed. In case of an adverse event, the subject will be asked to immediately contact the clinic, and to come to an unscheduled visit if needed. At each of the two follow-up visits and at the final visit, the investigator will evaluate the overall severity of seborrhea (ISGA) and the target area's erythema and desquamation. The subject will assess his/her pruritus over the past 24 hours. At the final visit, the subject will also complete a product-assessment questionnaire. The questionnaire will ask several questions about satisfaction attributes, using a 5-point scale: -2 = very unsatisfied, -1 = unsatisfied, 0 = neutral, +1 = satisfied, +2 = very satisfied. Attributes will include: overall satisfaction, speed of results, ease of use, ease of spread, comfort under makeup, feel on the skin (-2 = very greasy, +2 = very moisturizing), speed of absorption, texture, color and odor

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Seborrheic Dermatitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Interventional, open label, Safety/Efficacy Study
    Arm Type
    Experimental
    Arm Description
    SEBORRHEAMEDIS Face Cream Interventional 30
    Intervention Type
    Device
    Intervention Name(s)
    SEBORRHEAMEDIS Face Cream
    Intervention Description
    SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
    Primary Outcome Measure Information:
    Title
    Improvement of overall ISGA. Descriptive Name of scale. Physician dermatology evaluation.
    Time Frame
    Days 42
    Secondary Outcome Measure Information:
    Title
    Improvement of erythema, desquamation on the target area. Physiological parameter. Physician dermatology evaluation.
    Time Frame
    Days 0, 14, 28 and 42
    Title
    Improvement of pruritus. Physiological parameter. Assessed by subject.
    Time Frame
    Days 0, 14, 28 and 42
    Title
    Number and severity of Adverse Events
    Time Frame
    Days 0, 14, 28 and 42

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject with mild (ISGA=2) to moderate (ISGA=3) facial Seborrheic dermatitis. Male or female aged 18 years or older. Subject who agrees not to use any Seborrheic Dermatitis medication during the study, except for the tested product. Subject is willing to sign an Informed Consent Exclusion Criteria: Subject pregnant or lactating. Subject has a condition that requires continuous systemic or topical corticosteroid or antimycotic therapy Subject has a severe disease that is likely to interfere with the study conducting Subject has a known sensitivity to any of the ingredients contained in the tested product. Subject is expected to be extensively exposed to the sun during the study
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Rubén del Rio Gil, MD
    Organizational Affiliation
    Hospital de l'Esperit Sant
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    28458770
    Citation
    Barak-Shinar D, Del Rio R, Green LJ. Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream. J Clin Aesthet Dermatol. 2017 Apr;10(4):17-23.
    Results Reference
    derived

    Learn more about this trial

    Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis

    We'll reach out to this number within 24 hrs